AREG and ovarian cancer: Our analysis of publicly available datasets revealed AREG’s upregulation in chemoresistant ovarian cancer patients, further strengthening our previous observation of AREG’s significant upregulation in HGSOC patient tumors following exposure to frontline carboplatin and paclitaxel (James et al., 2022).